comprehensive -WSS

comprehensive

author：explore 2025-08-19 15:02:13 - browse：63

Blood corpuscles in clot — Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success. David Gregory & Debbie Marshall/Wellcome Images

Vascular device maker Inari Medical announced plans to buy LimFlow, a company selling a last-line therapy to save legs with blocked blood flow, on Wednesday. Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success.

LimFlow recently snagged Food and Drug Administration approval for its surgical system that uses a stent to connect a blocked artery to an open vein, thus allowing blood to flow through and heal injuries. The tool is meant only for patients with a severe form of peripheral artery disease, and who have already tried more conservative options.

Dan Rose, CEO of LimFlow, previously told STAT that his mission is to fight the amputation epidemic in the United States, which disproportionately impacts Black patients. Experts cautioned to STAT that expanding screenings to catch the disease early is still the most important measure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Lasker Awards 2023: Winners in biomedical research

WSS

Prosthetic arm enables patients to feel the objects they grip

Scientists successfully use ultrasound imaging to map brain activity

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

What Congress can do to address the rural doctor shortage

Insmed lung disease drug hits target in key Phase 3 trial

Insmed lung disease drug hits target in key Phase 3 trial

knowledge

comprehensive

entertainment

Virginia high school admissions case could be legal follow

Thermo Fisher plant for manufacturing gene therapies to expand

Moonlake's readout produced a cash windfall. Risks remain

Prosthetic arm enables patients to feel the objects they grip

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Ukraine and a new approach to mental health in war

Drug repurposing or repositioning? The language matters

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

entertainment

Dark money group runs ads on China biotech bill

Dark money group runs ads on China biotech bill

First Opinion Podcast: What happens when kids become caregivers?

Average age of first period drops to 11.9 years, study shows

Why are Kaiser Permanente staff considering a strike?

Adam's Biotech Scorecard: Do Sarepta's exon

hotspot

leisure time

focus

focus